Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13697527 | 0.98 | CYP1A2 (0.34) | CTSLCTSBCTSKLMNACYP1A2 | |
| SCHEMBL15684448 | 0.90 | — | — | |
| SCHEMBL14598913 | 0.85 | ALDH1A1 (0.32) | — | |
| SCHEMBL23383095 | 0.82 | CTSL (0.33) | CTSLCTSBCTSK | |
| SCHEMBL14338963 | 0.81 | CTSL (0.39) | CTSLCTSBCTSKLMNACYP1A2 | |
| SCHEMBL18455136 | 0.79 | TDP1 (0.44) | — | |
| SCHEMBL19749310 | 0.79 | SHBG (0.31) | — | |
| SCHEMBL6177197 | 0.78 | SLC1A3 (0.33) | CTSLCTSBCTSKLMNA | |
| SCHEMBL87257 | 0.78 | — | — | |
| SCHEMBL22454265 | 0.78 | CTSL (0.31) | CTSLCTSBCTSKLMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305848-A1 | SULFONIUM SALT, PHOTOACID GENERATOR, AND PHOTOSENSITIVE COMPOSITION | TOKYO OHKA KOGYO CO., LTD. (JP) | 2017-10-26 | — | — | US | disclosed |
| US-20170305848-A1 | SULFONIUM SALT, PHOTOACID GENERATOR, AND PHOTOSENSITIVE COMPOSITION | TOKYO OHKA KOGYO CO., LTD. (JP) | 2017-10-26 | — | — | US | disclosed |
| EP-3199520-A1 | SULFONIUM SALT, PHOTOACID GENERATOR, AND PHOTOSENSITIVE COMPOSITION | Tokyo Ohka Kogyo Co., Ltd. (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-8759362-B2 | Bicycloheteroaryl compounds and their use as TRPV1 ligands | PURDUE PHARMA L.P. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8703962-B2 | Monocyclic compounds and their use as TRPV1 ligands | PURDUE PHARMA L.P. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8546388-B2 | Heterocyclic TRPV1 receptor ligands | PURDUE PHARMA L.P. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20100137306-A1 | HETEROCYCLIC TRPV1 RECEPTOR LIGANDS | PURDUE PHARMA L.P. | 2010-06-03 | — | — | US | disclosed |
| US-20100130499-A1 | BICYCLOHETEROARYL COMPOUNDS AND THEIR USE AS TRPV1 LIGANDS | PURDUE PHARMA L.P. | 2010-05-27 | — | — | US | disclosed |
| US-20100120862-A1 | MONOCYCLIC COMPOUNDS AND THEIR USE AS TRPV1 LIGANDS | PURDUE PHARMA L.P. | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130499-A1 | BICYCLOHETEROARYL COMPOUNDS AND THEIR USE AS TRPV1 LIGANDS | TRPV1, TRPA1, TRPV3 | CTSL 2260/4885CTSB 1507/4885CTSK 903/4885 |
| US-20170305848-A1 | SULFONIUM SALT, PHOTOACID GENERATOR, AND PHOTOSENSITIVE COMPOSITION | ARSA, SPIN1, ASIC1 | CTSL 3449/4885CTSB 3526/4885CTSK 2737/4885 |
| US-20100137306-A1 | HETEROCYCLIC TRPV1 RECEPTOR LIGANDS | TRPV1, TRPA1, TRPV2 | CTSL 3991/4885CTSB 2590/4885CTSK 2495/4885 |
| US-20100120862-A1 | MONOCYCLIC COMPOUNDS AND THEIR USE AS TRPV1 LIGANDS | TRPV1, TRPA1, TRPV2 | CTSL 3023/4885CTSB 1863/4885CTSK 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.